SYDNEY: Japan’s SoftBank raised $4.8 billion from a sale of 21.5 million T-Mobile shares at $224 each, according to a term sheet reviewed by Reuters. The shares were offered in a price range of ...

Reported Standalone quarterly numbers for Nagreeka Capital and Infrastructure are: Net Sales at Rs 15.92 crore in March 2025 down 34.79% from Rs. 24.42 crore in March 2024.

Sony's latest PS Store promotion is here, and this time, the sale is all about Remasters & Retro. It's active from now through to the end of 25th June 2025, so you don't have much time left to ...

Belmont Stakes payouts. Belmont Stakes payouts have been made available. Check back here to see the official race results from Saratoga. Belmont Stakes payout figures will include win, place, show ...

Stock needed to be placed on the 40-man roster. To make room there, Boston transferred righty Josh Winckowski to the 60-day injured list with a right elbow flexor strain.

About 75.24 million people were living in extreme poverty in India during 2022-23, a massive drop from 344.47 million in 2011-12.

1. IonQ. If I had to pick only one quantum computing stock that could make you a millionaire, it would probably be IonQ (IONQ 7.66%).The company, founded in 2005, has already achieved tremendous ...

Sovereignty, trained by Bill Mott and ridden by Junior Alvarado, won the 2025 Belmont Stakes at Saratoga Race Course.

Attendance Allowance provides either £73.90 (lower rate) or £110.40 (higher rate) weekly. As payments are made every four weeks, recipients will receive either £295.60 or £441.60 per payment ...

During today's trading session, ABB India experienced a notable increase, with its shares rising by 2.06% to reach Rs 6155.50. This increase reflects a positive shift in market sentiment towards ...

Stonepeak Partners is reportedly in talks to acquire Malaysian energy firm Yinson Holdings for $2.1 billion, in a deal that would take the company private with support from its founding Lim family.

Otsuka Pharmaceutical has shared more detailed data behind its kidney disease drug’s phase 3 win, showing the monoclonal antibody halved patients’ urine protein-to-creatinine ratio (UPCR) levels.